Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 12, 2017

View Archived Issues

Anti-CD73 A-001421 shows antitumor activity in experimental tumor models

Novel technique of rapid and robust diagnosis of Alzheimer's disease and various other dementias

TargomiRs demonstrates early signs of activity in patients with malignant pleural mesothelioma

Phase III trial of upadacitinib in rheumatoid arthritis meets all endpoints

Infant Bacterial Therapeutics reports topline safety data from phase II study of IBP-9414

MK-3866 studied in patients with impaired renal function

DelMar Pharmaceuticals commences phase II study of VAL-083 in GBM

EMA grants orphan drug designation to seladelpar for primary biliary cholangitis

New oncolytic measles virus-mediated delivery of PD-1-targeting antibody for cancer treatment

Marinus Pharmaceuticals reports results from phase II study in CDKL5 disorder

BARDA awards contract to Summit Therapeutics to develop ridinilazole for CDI

GSK initiates phase I study of acute pancreatitis treatment GSK-3335065

2017 Lasker awards recognize significance of HPV vaccine, mTOR

East China University of Science and Technology patents EGFR inhibitors

Taiho Pharmaceutical identifies RET inhibitors

DiaMedica Therapeutics begins phase II study of DM-199

Cantargia initiates phase I/II trial of CAN-04 in solid malignant tumors

DENV glycoprotein EDIII variants reported in Albert Einstein College of Medicine patent

Merck KGaA compares MSB-11455 to Neulasta in phase I studies

Global Alliance for TB Drug Development initiates phase I study of TBA-7371

Phase III LIBERTY ASTHMA QUEST study of dupilumab meets primary endpoints

The Osaka University discloses reoviruses for treating fibrosis

New phase I trial evaluates M-3541 with radiotherapy in patients with solid tumors

Bayer enters kidney disease collaboration with Vanderbilt University Medical Center

New malaria trial explores modifications to vaccine regimen of RTS,S

HitGen and Takeda establish drug discovery research collaboration

Canalia launched in Japan for type 2 diabetes

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2024.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for December 24, 2024.
Enhanced Cognition: Lewy body dementia phase II pumps stock
BioWorld
Investors will get more details during the International Lewy Body Dementia Conference in Amsterdam late next month, but Wall Street is already buzzing about...
Experimental mRNA gene therapy suppresses preeclampsia in mice
BioWorld MedTech
A gene therapy based on an enhanced lipid nanoparticle (LNP) loaded with vascular endothelial growth factor (VEGF) mRNA could be developed for the treatment of...
Drug duo to Repare lack in gyno cancers? Phase I shows promise
BioWorld
Wall Street wasn’t jumping up and down about Repare Therapeutics Inc.’s early data in gynecological cancers, though the findings look positive and the company has...

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.